[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.

[1]  Heather M. Hennkens,et al.  Radiometals for combined imaging and therapy. , 2013, Chemical reviews.

[2]  E. Krenning,et al.  [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study , 2012, EJNMMI Research.

[3]  J. Reubi,et al.  Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model. , 2010, European journal of pharmacology.

[4]  J. Rivier,et al.  Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  R. Valkema,et al.  Tumor imaging and therapy using radiolabeled somatostatin analogues. , 2009, Accounts of chemical research.

[6]  R. Riek,et al.  Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. , 2009, Journal of medicinal chemistry.

[7]  Jean E Rivier,et al.  Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. , 2008, Journal of medicinal chemistry.

[8]  R. Riek,et al.  Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity. , 2008, Journal of medicinal chemistry.

[9]  S. Schulz,et al.  New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting , 2008, Clinical Cancer Research.

[10]  S. Schulz,et al.  Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  J. Reubi,et al.  68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Martin A Walter,et al.  Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Christian Bruns,et al.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.

[14]  E. Krenning,et al.  Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  J. Reubi.  Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.

[16]  Marion de Jong,et al.  Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  T. Visser,et al.  The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  J. Reubi,et al.  A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. , 2002, European journal of pharmacology.

[19]  T. Quinn,et al.  In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy , 2002, International journal of cancer.

[20]  G. Loudos,et al.  [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  T. Visser,et al.  Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives , 2001, European Journal of Nuclear Medicine.

[22]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[23]  S. Lamberts,et al.  Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. , 1999, The Journal of clinical endocrinology and metabolism.

[24]  G. Mengod,et al.  Somatostatin receptor subtypes sst1, sst2, sst3 and sst5expression in human pituitary, gastroentero‐pancreatic and mammary tumors , 1997 .

[25]  M. T. Stephenson,et al.  Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. , 1997, Cancer research.

[26]  G. Capellá,et al.  Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. , 1996, Cancer research.

[27]  J. Reubi,et al.  Somatostatin receptors in human prostate and prostate cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[28]  H. Niznik,et al.  The somatostatin receptor family. , 1995, Life sciences.

[29]  G. Bell,et al.  Molecular biology of somatostatin receptors. , 1995, Endocrine reviews.

[30]  G. Mengod,et al.  Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. , 1994, Cancer research.

[31]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[32]  E. Krenning,et al.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.

[33]  J. Charboneau,et al.  Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. , 1990, Cancer research.

[34]  J. Klijn,et al.  Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. , 1988, Gastroenterology.

[35]  S. Bloom,et al.  Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. , 1981, Gut.

[36]  W. Vale,et al.  Somatostatin: analogs with selected biological activities. , 1977, Science.

[37]  J. Rivier,et al.  Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. , 2010, Molecular endocrinology.

[38]  D. Hoyer,et al.  Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230. , 2005, Journal of Endocrinological Investigation.

[39]  E. Krenning,et al.  Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. , 1999, Proceedings of the Association of American Physicians.

[40]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .

[41]  T. Wheatley,et al.  In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat. , 1983, Endocrinology.

[42]  A. Schally,et al.  [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release. , 1980, Proceedings of the National Academy of Sciences of the United States of America.